Vaccination coverage in the context of the emerging Yellow Fever threat in French Guiana.
Adolescent
Adult
Aged
Child
Child, Preschool
Cross-Sectional Studies
Demography
Disease Transmission, Infectious
/ prevention & control
Family Characteristics
Female
French Guiana
/ epidemiology
Humans
Male
Middle Aged
Socioeconomic Factors
Vaccination Coverage
/ statistics & numerical data
Yellow Fever
/ epidemiology
Yellow Fever Vaccine
/ administration & dosage
Young Adult
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
05
04
2019
accepted:
24
07
2019
revised:
29
08
2019
pubmed:
20
8
2019
medline:
8
1
2020
entrez:
20
8
2019
Statut:
epublish
Résumé
French Guiana, a French overseas department located in South America between Brazil and Surinam, is the only European territory geographically located in the Amazonian forest complex and is considered endemic for yellow fever (YF). In the context of the emergent threat of YF in Latin America, we conducted a large household cross-sectional survey from June to October 2017 to estimate vaccination coverage in the population and to determine associations with sociodemographic and geographical characteristics. In total, 1,415 households and 2,697 individuals were included from the 22 municipalities of French Guiana. YF vaccination coverage was estimated at 95.0% (95% CI: 93.4-96.2) in the entire territory but was spatially heterogeneous, with the lowest levels estimated in the western part of the territory along the Surinamese cross-border region, particularly in children under 16 years who were not enrolled in school, immigrant adults and disadvantaged populations with low socioeconomic indexes. Despite the good vaccination coverage against YF in the general population of French Guiana resulting from the compulsory nature of YF vaccination for residents and travelers, there is an urgent need to improve vaccination coverage in vulnerable populations living in the northwestern part of the territory to limit the risk of transmission in the context of the emerging YF threat in South America. Despite the relative rarity of YF and the significant number of infectious and tropical diseases in French Guiana, clinicians should adopt a high index of suspicion for YF, particularly in vulnerable and at-risk populations.
Sections du résumé
BACKGROUND
French Guiana, a French overseas department located in South America between Brazil and Surinam, is the only European territory geographically located in the Amazonian forest complex and is considered endemic for yellow fever (YF). In the context of the emergent threat of YF in Latin America, we conducted a large household cross-sectional survey from June to October 2017 to estimate vaccination coverage in the population and to determine associations with sociodemographic and geographical characteristics.
METHODOLOGY/PRINCIPAL FINDINGS
In total, 1,415 households and 2,697 individuals were included from the 22 municipalities of French Guiana. YF vaccination coverage was estimated at 95.0% (95% CI: 93.4-96.2) in the entire territory but was spatially heterogeneous, with the lowest levels estimated in the western part of the territory along the Surinamese cross-border region, particularly in children under 16 years who were not enrolled in school, immigrant adults and disadvantaged populations with low socioeconomic indexes.
CONCLUSIONS/SIGNIFICANCE
Despite the good vaccination coverage against YF in the general population of French Guiana resulting from the compulsory nature of YF vaccination for residents and travelers, there is an urgent need to improve vaccination coverage in vulnerable populations living in the northwestern part of the territory to limit the risk of transmission in the context of the emerging YF threat in South America. Despite the relative rarity of YF and the significant number of infectious and tropical diseases in French Guiana, clinicians should adopt a high index of suspicion for YF, particularly in vulnerable and at-risk populations.
Identifiants
pubmed: 31425507
doi: 10.1371/journal.pntd.0007661
pii: PNTD-D-19-00529
pmc: PMC6715233
doi:
Substances chimiques
Yellow Fever Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007661Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist
Références
Eur J Public Health. 2009 Apr;19(2):183-8
pubmed: 19221023
Am J Trop Med Hyg. 2017 Aug;97(2):344-355
pubmed: 28722640
PLoS Negl Trop Dis. 2016 Apr 29;10(4):e0004681
pubmed: 27128312
Lancet Infect Dis. 2001 Aug;1(1):11-20
pubmed: 11871403
MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):647-50
pubmed: 26086636
Euro Surveill. 2017 Nov;22(44):
pubmed: 29113627
Vaccine. 2007 Apr 12;25(15):2758-65
pubmed: 17368349
Euro Surveill. 2017 Jul 13;22(28):
pubmed: 28749337
J Clin Virol. 2015 Mar;64:160-73
pubmed: 25453327
PLoS One. 2017 Feb 14;12(2):e0172267
pubmed: 28196111
Public Health. 2018 May;158:15-24
pubmed: 29525571
Euro Surveill. 2014 Apr 03;19(13):
pubmed: 24721539
Euro Surveill. 2018 Sep;23(36):
pubmed: 30205871
Euro Surveill. 2017 Mar 16;22(11):
pubmed: 28333617
Rev Med Virol. 2008 Sep-Oct;18(5):331-46
pubmed: 18615782
J Am Med Inform Assoc. 2014 Oct;21(e2):e232-40
pubmed: 24549761
Stud Health Technol Inform. 2011;169:629-33
pubmed: 21893824
Wkly Epidemiol Rec. ;92(16):193-204
pubmed: 28429585
Braz J Infect Dis. 2017 Mar - Apr;21(2):123-124
pubmed: 28336123
Mem Inst Oswaldo Cruz. 2018 Sep 03;113(10):e180278
pubmed: 30427974
Lancet Infect Dis. 2011 Aug;11(8):622-32
pubmed: 21798462
Euro Surveill. 2016 Sep 29;21(39):
pubmed: 27719755
Lancet Infect Dis. 2018 Jan;18(1):28
pubmed: 29303736
N Engl J Med. 2017 Apr 13;376(15):1397-1399
pubmed: 28273000
Euro Surveill. 2016 Jul 14;21(28):
pubmed: 27447300
PLoS Negl Trop Dis. 2016 Nov 1;10(11):e0005081
pubmed: 27802275
Emerg Infect Dis. 1999 May-Jun;5(3):429-32
pubmed: 10341180
Theor Biol Med Model. 2018 Jul 2;15(1):9
pubmed: 29961429
N Engl J Med. 2016 Jul 28;375(4):301-3
pubmed: 27276108
Travel Med Infect Dis. 2017 Jan - Feb;15:37-44
pubmed: 27789244